Risk factor
Very high price volatility
Profitability factor
Undervalued vs peers
About
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Company Valuation
From both historical and forecast perspectives, the stock is underpriced compared to similar stocks.
Target Price
The average target price of NERV is 9.5 and suggests 47% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Buy
Sell